Health&Life Co

Health&Life Co EBIT Growth

The Year-over-Year EBIT Growth of Health&Life Co (1781.TWO) as of Nov 6, 2026 is -322.65 %. In the previous year, Year-over-Year EBIT Growth was 174.28 % — a change of -285.13% (lower).

EBIT Growth

-322.65 %

YoY

-285.13%

Last updated:

Year-over-Year EBIT Growth of Health&Life Co is 2025 -322.65 % . Year-over-Year EBIT Growth of Health&Life Co was 2024 174.28 % . It decreases by -285.13% lower compared to the previous year.

The Health&Life Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
13.35 TWD
Jan 1, 2019
-37.35 TWD
Jan 1, 2020
78.59 TWD
Jan 1, 2021
-477.49 TWD
Jan 1, 2022
53.47 TWD
Jan 1, 2023
11.26 TWD
Jan 1, 2024
174.28 TWD
Jan 1, 2025
-322.65 TWD
The Health&Life Co EBIT Growth history
YEAREBIT GrowthYoY
-322.65 %-285.13%
174.28 %+1,448.44%
11.26 %-78.95%
53.47 %-111.20%
-477.49 %-707.58%
78.59 %-310.41%
-37.35 %-379.76%
13.35 %-15.59%
15.82 %+51.03%
10.47 %+338.84%
2.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Year-over-Year EBIT Growth of Health&Life Co is -322.65 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Health&Life Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Health&Life Co

All Key Metrics — Health&Life Co